Stock Scorecard
Stock Summary for Keros Therapeutics Inc (KROS) - $15.25 as of 8/29/2025 3:34:09 PM EST
Total Score
15 out of 30
Safety Score
47 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for KROS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KROS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KROS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for KROS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for KROS (47 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 6 |
| Book Value to Price (Max of 10) | 8 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 2 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for KROS
Financial Details for KROS
Company Overview |
|
|---|---|
| Ticker | KROS |
| Company Name | Keros Therapeutics Inc |
| Country | USA |
| Description | Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 10/30/2025 |
Stock Price History |
|
| Last Day Price | 15.25 |
| Price 4 Years Ago | 58.51 |
| Last Day Price Updated | 8/29/2025 3:34:09 PM EST |
| Last Day Volume | 584,554 |
| Average Daily Volume | 468,909 |
| 52-Week High | 72.37 |
| 52-Week Low | 9.12 |
| Last Price to 52 Week Low | 67.21% |
Valuation Measures |
|
| Trailing PE | 47.66 |
| Industry PE | 40.47 |
| Sector PE | 60.89 |
| 5-Year Average PE | -8.19 |
| Free Cash Flow Ratio | 0.90 |
| Industry Free Cash Flow Ratio | 15.46 |
| Sector Free Cash Flow Ratio | 30.76 |
| Current Ratio Most Recent Quarter | 21.11 |
| Total Cash Per Share | 16.99 |
| Book Value Per Share Most Recent Quarter | 17.40 |
| Price to Book Ratio | 0.89 |
| Industry Price to Book Ratio | 28.68 |
| Sector Price to Book Ratio | 26.74 |
| Price to Sales Ratio Twelve Trailing Months | 2.66 |
| Industry Price to Sales Ratio Twelve Trailing Months | 25.19 |
| Sector Price to Sales Ratio Twelve Trailing Months | 13.32 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 40,615,400 |
| Market Capitalization | 619,384,850 |
| Institutional Ownership | 100.64% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -22.46% |
| Reported EPS 12 Trailing Months | 0.32 |
| Reported EPS Past Year | 2.86 |
| Reported EPS Prior Year | -5.01 |
| Net Income Twelve Trailing Months | 18,773,000 |
| Net Income Past Year | -187,353,000 |
| Net Income Prior Year | -152,992,000 |
| Quarterly Revenue Growth YOY | 49,003.00% |
| 5-Year Revenue Growth | -18.71% |
| Operating Margin Twelve Trailing Months | -219.20% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 690,215,000 |
| Total Cash Past Year | 559,931,000 |
| Total Cash Prior Year | 331,147,000 |
| Net Cash Position Most Recent Quarter | 690,215,000 |
| Net Cash Position Past Year | 559,931,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 4,956,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 571,553,000 |
| Total Stockholder Equity Prior Year | 332,213,000 |
| Total Stockholder Equity Most Recent Quarter | 706,734,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 53,080,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 1.31 |
| Free Cash Flow Past Year | -162,800,000 |
| Free Cash Flow Prior Year | -126,972,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.28 |
| MACD Signal | 0.16 |
| 20-Day Bollinger Lower Band | 13.04 |
| 20-Day Bollinger Middle Band | 14.22 |
| 20-Day Bollinger Upper Band | 15.40 |
| Beta | 1.34 |
| RSI | 61.54 |
| 50-Day SMA | 25.55 |
| 150-Day SMA | 39.41 |
| 200-Day SMA | 40.85 |
System |
|
| Modified | 8/30/2025 3:16:42 AM EST |